Invivoscribe has expanded a long-term agreement to develop and commercialize oncology assays for Thermo Fisher Scientific’s Ion PGM Dx system to also include developing tests for the Applied Biosystems 3500 Dx Series genetic analyzers. Under the terms of the new collaboration, Invivoscribe will seek Food and Drug Administration approval of an assay for mutations in the FMS-like tyrosine kinase 3 (FLT3) gene, as well as clearance for a number of B- and T-cell clonality and immuno-oncology assay kits that will run on Thermo Fisher’s 3500 Dx capillary electrophoresis platform. FLT3 is an important biomarker for stratifying and establishing prognosis in acute myeloid leukemia. The Invivoscribe FLT3 mutation test is a signal ratio assay that identifies both internal tandem duplication (ITD) and tyrosine kinase domain mutations in FLT3, and also identifies large ITD mutations, which many current next-generation sequencing–based assays miss.